By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Verinata Health today said that it has entered into a three-year supply deal with Illumina, under which it will purchase sequencing instruments and consumables for use in commercializing its prenatal diagnostics offerings.

Verinata is developing tests for detecting multiple aneuploidies. The San Carlos, Calif.-based firm said that in addition to the supply deal it will collaborate with Illumina on gaining regulatory approval for the testing service.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.